World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
34694
World Ranking
10815
National Ranking
386

Overview

Daniele Santini is affiliated with Università Campus Bio-Medico in Italy. Their primary research domain is medicine, with a specialization in oncology. Santini's work spans several subfields including oncology, pulmonary and respiratory medicine, surgery, cancer research, and molecular biology.

The scientist's recent publications cover a range of cancer-related topics. Notable papers include:

  • Bone health in cancer: ESMO Clinical Practice Guidelines, 2020, Annals of Oncology
  • The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline, 2022, Annals of Oncology
  • Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial, 2020, The Lancet Oncology
  • Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice, 2020, Journal for ImmunoTherapy of Cancer
  • Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples, 2020, Journal of Experimental & Clinical Cancer Research

Frequent collaborators of Santini include:

  • Giuseppe Tonini (58 co-authored papers)
  • Sebastiano Buti (56 co-authored papers)
  • Ugo De Giorgi (56 co-authored papers)
  • Bruno Vincenzi (51 co-authored papers)
  • Giuseppe Procopio (51 co-authored papers)

Santini has published extensively in the following venues:

  • Annals of Oncology (40 publications)
  • Journal of Clinical Oncology (36 publications)
  • ESMO Open (19 publications)
  • Frontiers in Oncology (13 publications)
  • Cancers (12 publications)

The main research topics examined by Daniele Santini include:

  • Cancer Immunotherapy and Biomarkers
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Treatments and Mutations
  • Renal cell carcinoma treatment
  • Cancer Genomics and Diagnostics
  • Cancer Treatment and Pharmacology
  • Bladder and Urothelial Cancer Treatments

Best Publications

  • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter

  • KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

    F Loupakis;A Ruzzo;C Cremolini;B Vincenzi

  • Management of cancer pain: ESMO Clinical Practice Guidelines

    C. I. Ripamonti;D. Santini;E. Maranzano;M. Berti

  • Tissue invasion and metastasis: Molecular, biological and clinical perspectives.

    Wen Guo Jiang;Andrew James Sanders;M. Katoh;H. Ungefroren

  • PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

    Fotios Loupakis;Luca Pollina;Irene Stasi;Annamaria Ruzzo

  • Zoledronic Acid Induces Significant and Long-Lasting Modifications of Circulating Angiogenic Factors in Cancer Patients

    Daniele Santini;Bruno Vincenzi;Giordano Dicuonzo;Giuseppe Avvisati

  • PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.

    F Massari;M Santoni;C Ciccarese;D Santini

  • Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy

    Annamaria Ruzzo;Francesco Graziano;Fotios Loupakis;Eliana Rulli

  • Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.

    Chiara Cremolini;Daniele Rossini;Emanuela Dell’Aquila;Sara Lonardi

  • Pamidronate Induces Modifications of Circulating Angiogenetic Factors in Cancer Patients

    Daniele Santini;Bruno Vincenzi;Giuseppe Avvisati;Giordano Dicuonzo

  • Designing a broad-spectrum integrative approach for cancer prevention and treatment

    Keith I. Block;Charlotte Gyllenhaal;Leroy Lowe;Amedeo Amedei

  • BONE HEALTH IN CANCER: ESMO CLINICAL PRACTICE GUIDELINES

    R. Coleman;P. Hadji;J.-J. Body;D. Santini

  • A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

    Alessio Cortellini;Melissa Bersanelli;Sebastiano Buti;Katia Cannita

  • High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.

    Daniele Santini;Fotios Loupakis;Bruno Vincenzi;Irene Floriani

  • Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

    Chiara Cremolini;Carlotta Antoniotti;Daniele Rossini;Sara Lonardi

  • Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer.

    Giuseppe Perrone;Pier Adelchi Ruffini;Vincenzo Catalano;Cathie Spino

  • Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

    D. Santini;B. Vincenzi;R. Addeo;C. Garufi

  • Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.

    Dino Amadori;Massimo Aglietta;Barbara Alessi;Lorenzo Gianni

  • Pamidronate (P) induces modifications of circulating angiogenetic factors in cancer patients

    D. Santini;B. Vincenzi;G. Di Cuonzo;F. Battistoni

  • KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

    A. Ruzzo;F. Loupakis;E. Canestrari;Chiara Cremolini

Frequent Co-Authors

Giuseppe Tonini
Giuseppe Tonini Università Campus Bio-Medico
Bruno Vincenzi
Bruno Vincenzi Università Campus Bio-Medico
Alfredo Falcone
Alfredo Falcone University of Pisa
Stefano Cascinu
Stefano Cascinu Vita-Salute San Raffaele University
Antonio Russo
Antonio Russo University of Palermo
Fotios Loupakis
Fotios Loupakis Istituto Oncologico Veneto
Nicola Silvestris
Nicola Silvestris University of Messina
Alfonso Baldi
Alfonso Baldi University of Campania "Luigi Vanvitelli"
Sara Lonardi
Sara Lonardi Istituto Oncologico Veneto
Ugo De Giorgi
Ugo De Giorgi The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always mean following the traditional route of medical school. There are a wide range of related online degrees and career pathways that can help students and working professionals enter or advance in healthcare. Many of these programs are designed for flexibility and affordability, making them accessible no matter your location or schedule.

For those interested in administrative roles, earning a medical coding certification online is a practical option. It opens doors to positions in healthcare information management and insurance billing, with high demand for certified professionals.

Nursing remains one of the most popular and rewarding healthcare fields. Prospective students can find a variety of online nursing school programs for entry-level and advanced studies. If you're looking for specialization and higher earning potential, the most affordable nurse practitioner programs offer a pathway to advanced clinical roles.

For those considering a future in research, teaching, or leadership, the cheapest PhD nursing programs are designed for working nurses to pursue doctoral-level education online.

Best Scientists Citing Daniele Santini

Trending Scientists